T1	CHEM 13 25	trandolapril
#1	AnnotatorNotes T1	C0076891; trandolapril; Organic Chemical · Pharmacologic Substance
T2	PROC 29 40	monoterapia
#2	AnnotatorNotes T2	C4763675; Single Agent Therapy; Therapeutic or Preventive Procedure
T3	CHEM 56 65	verapamil
#3	AnnotatorNotes T3	C0042523; verapamil; Organic Chemical · Pharmacologic Substance
T4	DISO 94 105	albuminuria
#4	AnnotatorNotes T4	C0001925; Albuminuria; Finding
T5	PROC 904 907	EUA
#5	AnnotatorNotes T5	C0585937; Albumin excretion rate measurement; Laboratory Procedure
T6	DISO 140 151	hipertensos
#6	AnnotatorNotes T6	C0020538; Hypertensive disease; Disease or Syndrome
T7	DISO 156 171	diabetes tipo 2
#7	AnnotatorNotes T7	C0011860; Diabetes Mellitus, Non-Insulin-Dependent; Disease or Syndrome
T8	DISO 174 185	albuminuria
#8	AnnotatorNotes T8	C0001925; Albuminuria; Finding
T9	DISO 190 201	proteinuria
#9	AnnotatorNotes T9	C0033687; Proteinuria; Finding
T10	DISO 251 262	hipertensos
#10	AnnotatorNotes T10	C0020538; Hypertensive disease; Disease or Syndrome
T11	DISO 267 282	diabetes tipo 2
#11	AnnotatorNotes T11	C0011860; Diabetes Mellitus, Non-Insulin-Dependent; Disease or Syndrome
T12	CHEM 288 293	IECAs
#12	AnnotatorNotes T12	C0003015; Angiotensin-Converting Enzyme Inhibitors; Pharmacologic Substance
T13	CHEM 298 306	fármacos
#13	AnnotatorNotes T13	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T14	CHEM 393 415	antagonista del calcio
#14	AnnotatorNotes T14	C0006684; Calcium Channel Blockers; Pharmacologic Substance
T15	CHEM 419 436	dihidropiridínico
#15	AnnotatorNotes T15	C0012315; Dihydropyridines; Organic Chemical · Pharmacologic Substance | C0220821; dihydropyridine; Organic Chemical · Pharmacologic Substance
T16	PROC 76 92	presión arterial
#16	AnnotatorNotes T16	C0005824; Blood pressure determination; Health Care Activity
T17	PROC 644 646	PA
#17	AnnotatorNotes T17	C0005824; Blood pressure determination; Health Care Activity
T18	PROC 523 534	tratamiento
#18	AnnotatorNotes T18	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T19	CHEM 547 559	trandolapril
#19	AnnotatorNotes T19	C0076891; trandolapril; Organic Chemical · Pharmacologic Substance
T20	PROC 564 575	monoterapia
#20	AnnotatorNotes T20	C4763675; Single Agent Therapy; Therapeutic or Preventive Procedure
T21	CHEM 589 598	verapamil
#21	AnnotatorNotes T21	C0042523; verapamil; Organic Chemical · Pharmacologic Substance
T22	ANAT 619 627	urinaria
#22	AnnotatorNotes T22	C0042036; Urine; Body Substance
T23	CHEM 631 639	albúmina
#23	AnnotatorNotes T23	C0001924; Albumins; Amino Acid, Peptide, or Protein · Biologically Active Substance
T24	PROC 1446 1451	HbAlc
#24	AnnotatorNotes T24	C0202054; Glucohemoglobin measurement; Laboratory Procedure | C0474680; Hemoglobin A1c measurement; Laboratory Procedure
T25	DISO 684 695	hipertensos
#25	AnnotatorNotes T25	C0020538; Hypertensive disease; Disease or Syndrome
T26	DISO 700 715	diabetes tipo 2
#26	AnnotatorNotes T26	C0011860; Diabetes Mellitus, Non-Insulin-Dependent; Disease or Syndrome
T27	DISO 718 729	proteinuria
#27	AnnotatorNotes T27	C0033687; Proteinuria; Finding
T28	PROC 731 786	Estudio multicéntrico, prospectivo, secuencial, abierto
#28	AnnotatorNotes T28	C1519252; Sequential Treatment; Therapeutic or Preventive Procedure + C1096776; Multicenter Study; Research Activity + C0033522; Prospective Studies; Research Activity + C1709323; Open Label Study; Research Activity
T29	CHEM 820 836	antihipertensivo
#29	AnnotatorNotes T29	C0003364; Antihypertensive Agents; Pharmacologic Substance
T30	ANAT 882 890	urinaria
#30	AnnotatorNotes T30	C0042036; Urine; Body Substance
T31	CHEM 894 902	albúmina
#31	AnnotatorNotes T31	C0001924; Albumins; Amino Acid, Peptide, or Protein · Biologically Active Substance
T32	PROC 932 934	PA
#32	AnnotatorNotes T32	C0005824; Blood pressure determination; Health Care Activity
T33	CHEM 1005 1013	mercurio
#33	AnnotatorNotes T33	C0025424; mercury; Hazardous or Poisonous Substance · Element, Ion, or Isotope
T34	PROC 1025 1036	Tratamiento
#34	AnnotatorNotes T34	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T35	CHEM 1049 1061	trandolapril
#35	AnnotatorNotes T35	C0076891; trandolapril; Organic Chemical · Pharmacologic Substance
T36	PROC 1118 1120	PA
#36	AnnotatorNotes T36	C0005824; Blood pressure determination; Health Care Activity
T37	PROC 1147 1149	PA
#37	AnnotatorNotes T37	C0005824; Blood pressure determination; Health Care Activity
T38	CHEM 1169 1178	verapamil
#38	AnnotatorNotes T38	C0042523; verapamil; Organic Chemical · Pharmacologic Substance
T39	PROC 1465 1476	Albuminuria
#39	AnnotatorNotes T39	C1318429; Urine albumin measurement; Laboratory Procedure
T40	PROC 1534 1545	tratamiento
#40	AnnotatorNotes T40	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T41	PROC 1523 1526	EUA
#41	AnnotatorNotes T41	C0585937; Albumin excretion rate measurement; Laboratory Procedure
T42	DISO 1633 1644	albuminuria
#42	AnnotatorNotes T42	C0001925; Albuminuria; Finding
T43	PROC 1726 1728	PA
#43	AnnotatorNotes T43	C0005824; Blood pressure determination; Health Care Activity
T44	CHEM 1850 1862	trandolapril
#44	AnnotatorNotes T44	C0076891; trandolapril; Organic Chemical · Pharmacologic Substance
T45	PROC 1867 1878	monoterapia
#45	AnnotatorNotes T45	C4763675; Single Agent Therapy; Therapeutic or Preventive Procedure
T46	CHEM 1892 1901	verapamil
#46	AnnotatorNotes T46	C0042523; verapamil; Organic Chemical · Pharmacologic Substance
T47	DISO 1967 1978	albuminuria
#47	AnnotatorNotes T47	C0001925; Albuminuria; Finding
T48	PROC 2007 2009	PA
#48	AnnotatorNotes T48	C0005824; Blood pressure determination; Health Care Activity
T49	PROC 1790 1795	HbAlc
#49	AnnotatorNotes T49	C0202054; Glucohemoglobin measurement; Laboratory Procedure | C0474680; Hemoglobin A1c measurement; Laboratory Procedure
T50	ANAT 84 92	arterial
#50	AnnotatorNotes T50	C0003842; Arteries; Body Part, Organ, or Organ Component | C1285085; Entire artery; Body Part, Organ, or Organ Component
T51	CHEM 542 546	IECA
#51	AnnotatorNotes T51	C0003015; Angiotensin-Converting Enzyme Inhibitors; Pharmacologic Substance
T52	PROC 609 639	excreción urinaria de albúmina
#52	AnnotatorNotes T52	C0585937; Albumin excretion rate measurement; Laboratory Procedure
T53	PROC 872 902	excreción urinaria de albúmina
#53	AnnotatorNotes T53	C0585937; Albumin excretion rate measurement; Laboratory Procedure
T54	PROC 1377 1380	PAS
#54	AnnotatorNotes T54	C1306620; Systolic blood pressure measurement; Diagnostic Procedure
T55	PROC 1381 1384	PAD
#55	AnnotatorNotes T55	C1305849; Diastolic blood pressure measurement; Diagnostic Procedure
T56	PROC 1416 1424	Glucemia
#56	AnnotatorNotes T56	C0392201; Blood glucose measurement; Laboratory Procedure
T57	PROC 1733 1741	glucemia
#57	AnnotatorNotes T57	C0392201; Blood glucose measurement; Laboratory Procedure
T59	LIVB 130 139	pacientes
#58	AnnotatorNotes T59	C0030705; Patients; Patient or Disabled Group
T60	LIVB 241 250	pacientes
#59	AnnotatorNotes T60	C0030705; Patients; Patient or Disabled Group
T61	LIVB 328 337	pacientes
#60	AnnotatorNotes T61	C0030705; Patients; Patient or Disabled Group
T64	Neg_cue 416 418	no
T65	PHYS 609 627	excreción urinaria
#61	AnnotatorNotes T65	C0042034; Urination; Organism Function | C2371165; Urination functions; Organ or Tissue Function
T66	LIVB 674 683	pacientes
#62	AnnotatorNotes T66	C0030705; Patients; Patient or Disabled Group
T67	Duration 840 849	4 semanas
T68	PHYS 872 890	excreción urinaria
#63	AnnotatorNotes T68	C0042034; Urination; Organism Function | C2371165; Urination functions; Organ or Tissue Function
T69	Duration 912 920	24 horas
T70	DEVI 985 1001	esfigmomanómetro
#64	AnnotatorNotes T70	C0183427; Sphygmomanometers; Medical Device
T71	Dose 1062 1066	2 mg
T72	Frequency 1066 1070	/día
T73	LIVB 1078 1087	pacientes
#65	AnnotatorNotes T73	C0030705; Patients; Patient or Disabled Group
T76	Dose 1179 1185	180 mg
T77	Duration 1188 1201	las 8 semanas
T78	Duration 1225 1235	12 semanas
T79	LIVB 1241 1250	pacientes
#66	AnnotatorNotes T79	C0030705; Patients; Patient or Disabled Group
T80	LIVB 1339 1346	hombres
#67	AnnotatorNotes T80	C0025266; Male population group; Population Group
T81	Age 1360 1375	61,7 ± 9,2 años
T88	LIVB 1680 1689	pacientes
#68	AnnotatorNotes T88	C0030705; Patients; Patient or Disabled Group
T89	LIVB 1701 1710	pacientes
#69	AnnotatorNotes T89	C0030705; Patients; Patient or Disabled Group
T91	LIVB 1836 1845	pacientes
#70	AnnotatorNotes T91	C0030705; Patients; Patient or Disabled Group
T92	PHYS 108 126	control metabólico
#71	AnnotatorNotes T92	C1513158; Metabolic Control; Molecular Function
T94	PHYS 652 670	control metabólico
#72	AnnotatorNotes T94	C1513158; Metabolic Control; Molecular Function
T98	LIVB 1316 1325	población
#73	AnnotatorNotes T98	C1257890; Population; Population Group
T101	PHYS 2024 2042	control metabólico
#74	AnnotatorNotes T101	C1513158; Metabolic Control; Molecular Function
A1	Assertion T15 Negated
R1	Negation Arg1:T64 Arg2:T15	
T58	Observation 1091 1104	respondedores
A2	Assertion T58 Negated
#75	AnnotatorNotes T58	C0919876; Therapy responder; Finding
T62	Neg_cue 1088 1090	no
R2	Negation Arg1:T62 Arg2:T58	
R3	Has_Quantifier_or_Qualifier Arg1:T73 Arg2:T58	
T63	Quantifier_or_Qualifier 1134 1145	controlados
A3	Assertion T63 Negated
T74	Neg_cue 1131 1133	no
R4	Negation Arg1:T74 Arg2:T63	
R5	Has_Quantifier_or_Qualifier Arg1:T73 Arg2:T63	
T75	Neg_cue 355 357	no
T82	Quantifier_or_Qualifier 361 371	suficiente
A4	Assertion T82 Negated
R6	Negation Arg1:T75 Arg2:T82	
T83	Spec_cue 437 443	podría
T84	CONC 452 463	alternativa
A5	Assertion T84 Speculated
#76	AnnotatorNotes T84	C1523987; Alternative; Qualitative Concept
T85	Quantifier_or_Qualifier 464 470	eficaz
A6	Assertion T85 Speculated
#77	AnnotatorNotes T85	C1280519; Effectiveness; Qualitative Concept
T86	Result_or_Value 1645 1658	se negativizó
R8	Used_for Arg1:T1 Arg2:T2	
R9	Combined_with Arg1:T1 Arg2:T3	
R10	Location_of Arg1:T50 Arg2:T16	
T87	Observation 1 8	Efectos
#78	AnnotatorNotes T87	C1518681; Outcome of Therapy; Finding (?)
R11	Causes Arg1:T1 Arg2:T87	
R12	Experiences Arg1:T59 Arg2:T6	
R13	Overlap Arg1:T6 Arg2:T7	
R14	Experiences Arg1:T59 Arg2:T8	
R15	Experiences Arg1:T59 Arg2:T7	
R16	Overlap Arg1:T6 Arg2:T8	
R17	Experiences Arg1:T59 Arg2:T92	
R18	Experiences Arg1:T59 Arg2:T4	
R19	Experiences Arg1:T59 Arg2:T16	
R20	Experiences Arg1:T59 Arg2:T1	
R21	Experiences Arg1:T59 Arg2:T87	
T90	Observation 221 237	morbi-mortalidad
R23	Experiences Arg1:T60 Arg2:T9	
R24	Overlap Arg1:T10 Arg2:T11	
R25	Overlap Arg1:T9 Arg2:T11	
R26	Experiences Arg1:T60 Arg2:T10	
R27	Experiences Arg1:T60 Arg2:T11	
R28	Experiences Arg1:T60 Arg2:T12	
R29	Experiences Arg1:T60 Arg2:T13	
R30	Has_Quantifier_or_Qualifier Arg1:T84 Arg2:T85	
R31	Speculation Arg1:T83 Arg2:T84	
R32	Speculation Arg1:T83 Arg2:T85	
T93	Observation 345 354	respuesta
#79	AnnotatorNotes T93	C1319171; Medication response; Finding
R33	Experiences Arg1:T61 Arg2:T93	
R34	Has_Quantifier_or_Qualifier Arg1:T93 Arg2:T82	
R35	Overlap Arg1:T93 Arg2:T14	
R36	Overlap Arg1:T93 Arg2:T15	
R37	Experiences Arg1:T61 Arg2:T14	
R38	Experiences Arg1:T61 Arg2:T15	
R39	Experiences Arg1:T61 Arg2:T13	
R40	Experiences Arg1:T61 Arg2:T12	
R41	Experiences Arg1:T61 Arg2:T11	
R42	Experiences Arg1:T61 Arg2:T10	
R43	Experiences Arg1:T61 Arg2:T90	
R44	Experiences Arg1:T61 Arg2:T9	
R45	Experiences Arg1:T60 Arg2:T93	
R46	Experiences Arg1:T60 Arg2:T14	
R47	Experiences Arg1:T60 Arg2:T15	
R48	Overlap Arg1:T12 Arg2:T93	
R49	Overlap Arg1:T13 Arg2:T93	
T95	Quantifier_or_Qualifier 307 318	de elección
R50	Has_Quantifier_or_Qualifier Arg1:T13 Arg2:T95	
R51	Overlap Arg1:T9 Arg2:T10	
R52	Overlap Arg1:T7 Arg2:T8	
T96	Observation 512 518	efecto
#80	AnnotatorNotes T96	C1518681; Outcome of Therapy; Finding (?)
R53	Causes Arg1:T18 Arg2:T96	
R54	Used_for Arg1:T51 Arg2:T18	
R55	Used_for Arg1:T19 Arg2:T18	
R56	Used_for Arg1:T51 Arg2:T20	
R57	Used_for Arg1:T19 Arg2:T20	
R58	Combined_with Arg1:T19 Arg2:T21	
R59	Location_of Arg1:T22 Arg2:T65	
R60	Location_of Arg1:T22 Arg2:T52	
R63	Experiences Arg1:T66 Arg2:T25	
R64	Experiences Arg1:T66 Arg2:T26	
R65	Experiences Arg1:T66 Arg2:T27	
R66	Overlap Arg1:T25 Arg2:T26	
R67	Overlap Arg1:T26 Arg2:T27	
R68	Overlap Arg1:T25 Arg2:T27	
R69	Experiences Arg1:T66 Arg2:T94	
R70	Experiences Arg1:T66 Arg2:T17	
R71	Experiences Arg1:T66 Arg2:T52	
R72	Experiences Arg1:T66 Arg2:T65	
R73	Experiences Arg1:T66 Arg2:T19	
R74	Experiences Arg1:T66 Arg2:T51	
R75	Experiences Arg1:T66 Arg2:T18	
R76	Experiences Arg1:T66 Arg2:T96	
R77	Experiences Arg1:T66 Arg2:T20	
R78	Causes Arg1:T20 Arg2:T96	
T97	CONC 788 819	período de lavado farmacológico
#81	AnnotatorNotes T97	C1710661; Washout Period; Temporal Concept
R82	Has_Duration_or_Interval Arg1:T97 Arg2:T67	
R83	Has_Quantifier_or_Qualifier Arg1:T97 Arg2:T29	
R84	Location_of Arg1:T30 Arg2:T53	
R85	Location_of Arg1:T30 Arg2:T68	
R86	Location_of Arg1:T30 Arg2:T5	
R87	Overlap Arg1:T5 Arg2:T69	
R88	Overlap Arg1:T53 Arg2:T69	
T99	Quantifier_or_Qualifier 945 952	3 tomas
R89	Has_Quantifier_or_Qualifier Arg1:T32 Arg2:T99	
T100	Observation 953 967	en sedestación
#82	AnnotatorNotes T100	C0277814; Sitting position; Finding
R90	Overlap Arg1:T32 Arg2:T100	
T102	CONC 973 979	reposo
#83	AnnotatorNotes T102	C0443144; At rest (qualifier value); Functional Concept
R91	After Arg1:T32 Arg2:T102	
R92	Used_for Arg1:T70 Arg2:T32	
R93	Used_for Arg1:T33 Arg2:T70	
T103	Quantifier_or_Qualifier 1014 1023	calibrado
R94	Has_Quantifier_or_Qualifier Arg1:T70 Arg2:T103	
R95	Used_for Arg1:T35 Arg2:T34	
R96	Has_Dose_or_Strength Arg1:T35 Arg2:T71	
R97	Has_Frequency Arg1:T35 Arg2:T72	
R98	Experiences Arg1:T73 Arg2:T34	
T104	Quantifier_or_Qualifier 1037 1044	inicial
#84	AnnotatorNotes T104	C0205265; Initially; Temporal Concept
R99	Has_Quantifier_or_Qualifier Arg1:T34 Arg2:T104	
R100	Experiences Arg1:T73 Arg2:T36	
T105	Observation 1106 1120	descenso de PA
#85	AnnotatorNotes T105	C0520854; Decreased mean arterial pressure; Finding (?)
R101	Experiences Arg1:T73 Arg2:T105	
R102	Experiences Arg1:T73 Arg2:T37	
R103	Experiences Arg1:T73 Arg2:T38	
R104	Has_Dose_or_Strength Arg1:T38 Arg2:T76	
R105	Has_Duration_or_Interval Arg1:T38 Arg2:T77	
R106	Before Arg1:T34 Arg2:T58	
R107	Before Arg1:T34 Arg2:T105	
R108	Before Arg1:T58 Arg2:T38	
R109	Before Arg1:T105 Arg2:T38	
T106	PROC 1216 1223	estudio
#86	AnnotatorNotes T106	C0681814; research study; Research Activity
R110	Has_Duration_or_Interval Arg1:T106 Arg2:T78	
T107	Observation 1251 1273	finalizaron el estudio
T108	CONC 1279 1302	características basales
#87	AnnotatorNotes T108	C1442488; Baseline; Quantitative Concept
R112	Has_Age Arg1:T80 Arg2:T81	
R113	Has_Age Arg1:T98 Arg2:T81	
R114	Combined_with Arg1:T35 Arg2:T38	
T109	Observation 1501 1510;1517 1526	Reducción de la EUA
R116	Causes Arg1:T40 Arg2:T109	
R117	Has_Result_or_Value Arg1:T42 Arg2:T86	
R118	Experiences Arg1:T88 Arg2:T42	
R119	Experiences Arg1:T88 Arg2:T86	
#88	AnnotatorNotes T86	C0205160; Negative; Finding
R120	Experiences Arg1:T89 Arg2:T43	
T110	Observation 1733 1751	glucemia descendió
R122	Experiences Arg1:T91 Arg2:T44	
R123	Experiences Arg1:T91 Arg2:T45	
R124	Used_for Arg1:T44 Arg2:T45	
R125	Combined_with Arg1:T44 Arg2:T46	
T111	Observation 1938 1944;1964 1978	reduce la albuminuria
R126	Overlap Arg1:T111 Arg2:T47	
R127	Experiences Arg1:T91 Arg2:T111	
R128	Experiences Arg1:T91 Arg2:T47	
R129	Experiences Arg1:T91 Arg2:T48	
R130	Experiences Arg1:T91 Arg2:T101	
R131	Causes Arg1:T44 Arg2:T111	
R132	Causes Arg1:T45 Arg2:T111	
#89	AnnotatorNotes T110	C0017746; Decreased glucose level; Finding
#90	AnnotatorNotes T107	C2732579; Completion of clinical trial; Finding
R80	Overlap Arg1:T4 Arg2:T6	
R81	Overlap Arg1:T4 Arg2:T7	
#91	AnnotatorNotes T82	C0205410; Sufficient; Qualitative Concept
#92	AnnotatorNotes T95	C0439608; elective; Temporal Concept (?)
A7	Experiencer T59 Patient
A8	Experiencer T60 Patient
A9	Experiencer T61 Patient
A10	Experiencer T66 Patient
A11	Experiencer T73 Patient
A12	Experiencer T79 Patient
A13	Experiencer T98 Patient
A14	Experiencer T80 Patient
A15	Experiencer T88 Patient
A16	Experiencer T89 Patient
A17	Experiencer T91 Patient
R7	Has_Result_or_Value Arg1:T36 Arg2:T105	
R22	Has_Result_or_Value Arg1:T41 Arg2:T109	
R61	Has_Result_or_Value Arg1:T57 Arg2:T110	
